The test – Check4-COVID™ – will require no prescription, no nasal swabs, no
mailed samples or waiting in line. The test’s greatest advantage is its
ability to accurately detect asymptomatic and early infections on a molecular
level – a significant weakness in home tests recently approved.
“Chemical-based home tests do not detect the virus on a genetic level and
often miss early and asymptomatic cases,” said IdentifySensors CEO Gregory
Hummer MD. “By the time someone gets sick and tested, the virus usually has
already spread. Our test catches early infections and asymptomatic cases
within minutes and without clinical intervention. This is a major breakthrough
in managing the pandemic.”
The electronically based test sends precise RNA results to a user’s smartphone
in minutes. Following FDA approval, anticipated early next year, Check4-COVID™
intends to be an over-the-counter, entirely at-home self-test with accuracy
that meets or exceeds the gold-standard in lab-grade testing.
“This new platform technology takes pathogen testing down a completely
different path than all the other diagnostic tests out there now,” said
Richard Kuhn, director of Purdue’s Institute of Inflammation, Immunology and
Infectious Disease. “Our COVID-19 testing research is showing very promising
results.”